ERresQ

Novel cell stress regulators for treating neurodegenerative and metabolic diseases

What we do

The ERresQ team has identified compounds that mimic the action of the neurotrophic factors MANF and CDNF, central regulators of cellular stress, survival, inflammation, and immune response. Our repurposed assets ERQ-01, ERQ-03, and ERQ-04, along with a new chemical entity ERQ-02, specifically target injured, stressed cells, thereby minimizing side effects. Our therapeutics will treat diabetes, Parkinson’s disease and amyotrophic lateral sclerosis (ALS) by protecting cells from death, regulating protein folding and reducing inflammation. Our goal is to advance the repurposed assets to phase II clinical trials (IITs) and to discover and develop new compounds that leverage this unique mechanism.

Contact us

00790, Helsinki, Finland

+358 44 943 7375

info@erresq.com